NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Lipocine, Inc. (NASDAQ: LPCN) resulting from allegations that Lipocine may have issued materially misleading business information to the investing public.
On June 29, 2016, Lipocine announced that the FDA issued a Complete Response Letter (“CRL”) concerning its New Drug Application for LPCN 102. The CRL identified issues related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form. In particular, the proposed titration scheme for clinical practice was significantly different from the titration scheme used in the Phase 3 trial leading to discordance in titration decisions between the Phase 3 trial and real-world clinical practice. On this news, shares of Lipocine fell $3.17 per share or over 50% to close at $3.01 per share on June 29, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Lipocine investors. If you purchased shares of Lipocine on or before June 28, 2016, please visit the website at http://rosenlegal.com/cases-918.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.